Marijuana drugmaker GW Pharmaceuticals Plc shares have returned an unbelievable 500% in the past year; trouncing the S&P 500 ETFs 23% return and handily outpacing the 37% return for the iShares Nasdaq Biotechnology ETF.
Given GW Pharma's meteoric rise, investors are right to wonder if there's more room left to run higher, or if the shares are ready to retreat, so let's take a closer look.
Elusive earnings and rising expenses
Emerging biotechnology companies like GW Pharma spend the majority of their cash developing new products or conducting trials to expand labels on existing medication.
